Fidelity Investments
PRLD icon

Fidelity Investments’s Prelude Therapeutics PRLD Stock Holding History

Fidelity Investments’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.6K Sell
6,009
-143
-2% -$375 ﹤0.01% 4503
2025
Q4 		$17.8K Sell
6,152
-2,947
-32% -$4.97K ﹤0.01% 4514
2025
Q3 		$13.1K Sell
9,099
-2,068
-19% -$2.07K ﹤0.01% 4525
2025
Q2 		$9.04K Sell
11,167
-9,071
-45% -$7.86K ﹤0.01% 4558
2025
Q1 		$15.5K Buy
20,238
+11,736
+138% +$10.9K ﹤0.01% 4325
2024
Q4 		$10.8K Buy
8,502
+884
+12% +$1.17K ﹤0.01% 4443
2024
Q3 		$15.8K Sell
7,618
-1,957
-20% -$9.06K ﹤0.01% 4283
2024
Q2 		$36.5K Sell
9,575
-1,975
-17% -$8.04K ﹤0.01% 3784
2024
Q1 		$54.7K Sell
11,550
-253,137
-96% -$985K ﹤0.01% 3541
2023
Q4 		$1.13M Sell
264,687
-4,866,746
-95% -$14.8M ﹤0.01% 2439
2023
Q3 		$15.9M Sell
5,131,433
-808,787
-14% -$3.03M ﹤0.01% 1672
2023
Q2 		$26.7M Buy
5,940,220
+1,393,542
+31% +$8.33M ﹤0.01% 1523
2023
Q1 		$25.9M Sell
4,546,678
-42,914
-0.9% -$262K ﹤0.01% 1512
2022
Q4 		$27.7M Sell
4,589,592
-48,955
-1% -$314K ﹤0.01% 1489
2022
Q3 		$30.7M Buy
4,638,547
+335,578
+8% +$2.26M ﹤0.01% 1446
2022
Q2 		$22.5M Sell
4,302,969
-1,068,938
-20% -$5.44M ﹤0.01% 1605
2022
Q1 		$37.1M Sell
5,371,907
-567,026
-10% -$5.19M ﹤0.01% 1518
2021
Q4 		$73.9M Sell
5,938,933
-1,116,733
-16% -$18.2M 0.01% 1253
2021
Q3 		$220M Buy
7,055,666
+503,167
+8% +$16.3M 0.02% 763
2021
Q2 		$188M Buy
6,552,499
+300,392
+5% +$10.7M 0.01% 855
2021
Q1 		$271M Buy
6,252,107
+2,042,144
+49% +$135M 0.02% 650
2020
Q4 		$296M Buy
4,209,963
+1,081,579
+35% +$53.8M 0.03% 584
2020
Q3 		$90.1M Buy
+3,128,384
New +$88.3M 0.01% 955

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Fidelity Investments's PRLD Position: Q1 2026 in Review

Fidelity Investments reduced its Prelude Therapeutics (PRLD) stake by 2.3% in Q1 2026, selling an estimated $375 and leaving 6,009 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4503.

Fidelity Investments first reported a position in PRLD in Q3 2020 and has held it in 23 quarters since. The position peaked at $296M in Q4 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Fidelity Investments held 6,009 shares of Prelude Therapeutics worth $20.6K as of Q1 2026.
  • Fidelity Investments sold 143 Prelude Therapeutics shares in Q1 2026, an estimated $375.
  • Prelude Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4503 holding.
  • Fidelity Investments first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Fidelity Investments's Prelude Therapeutics position peaked at $296M in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.